KAMI BELL: Open Payments
NPI 1417355694 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,527 in 68 payments from 11 companies in 2025. Trend: 2023 $1,416 · 2024 $1,569 · 2025 $1,527
Food & beverage: $1,486Education: $41
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 16 | $422 |
| Gilead Sciences, Inc. | 19 | $383 |
| Merck Sharp & Dohme LLC | 8 | $181 |
| Melinta Therapeutics, LLC | 9 | $155 |
| Astellas Pharma US Inc | 5 | $125 |
| Shionogi Inc | 3 | $93 |
| ABBVIE INC. | 4 | $90 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Insmed, Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
Products named: CABENUVA, DOVATO, Rezzayo, ZERBAXA, Fetroja, Cresemba, APRETUDE, AVYCAZ.
Industry payments across MS — which companies pay providers there.
